港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

海西新药

134.800

+2.8002.12%

成交量：3.33万

成交额：442.37万

市值：106.10亿

市盈率：- -

高：135.500

开：132.200

低：130.000

收：132.000

52周最高：147.000

52周最低：97.500

股本：7,870.73万

香港流通股本：7,870.73万

量比：0.33

换手率：0.04%

股息：- -

股息率：- -

净资产收益率：28.75%

总资产收益率：12.62%

市净率：17.93

市盈率(LYR):- -

市销率: 20.79

数据加载中...

总览公司新闻资讯公告

海西新药涨超10%再创新高，较招股价涨近七成！四款核心仿制药贡献九成收入

老虎资讯综合

港股异动 | 海西新药(02637)涨超10%再创新高较招股价涨近七成四款核心仿制药贡献九成收入

海西新药11月10日获主力加仓193.3万元

【IPO月报】10月IPO赚钱效应继续：金叶超购逾万倍长风药业首日可赚万七

海西新药10月30日主力净流入255.0万元散户资金抛售

10月19-25日港股IPO观察：5企业过聆讯，新能源与生物医药板块活跃

上市公司网

又一芯片龙头IPO过会丨IPO一周要闻

投资者网-思维财经

港股IPO | 刷新港股新记录！“高端中国茶第一股”八马茶业招股获热捧

尚普IPO咨询

海西新药10月24日主力净流出6.9万元散户资金买入

港股异动 | 海西新药(02637)一度涨超12% 较招股价涨超三成仿制药、创新药双线布局

又一药企登陆港股！医药行业赴港IPO热潮持续升温

异动解读 | 海西新药盘中大跌5.04%，高度依赖集采产品引发担忧

异动解读 | 海西新药盘中大跌5%，高度依赖集采产品引发担忧

港股综述｜三大指数齐涨！航空股延续近期涨势，机器人概念股集体“起飞”

老虎资讯综合

福建夫妇掌舵，海西新药IPO敲钟了

异动解读 | 海西新药上市首日盘中大涨21.53%，超额认购成热点

异动解读 | 海西新药上市首日大涨21.53%，IPO超额认购3165倍

新股定价 | 海西新药上限定价、今日挂牌，公开发售超购3164倍，一手中签率1%

老虎资讯综合

海西新药恢复周一上市，暗盘涨超50%！靠4款核心仿制药年入超4亿元

红星资本局

福建海西新药创制(2637)热度飙升逾31.6万份认购将于10月20日登陆港交所

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02637/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新药","latestPrice":134.8,"timestamp":1763366893757,"preClose":132,"halted":0,"volume":33300,"delay":0,"floatShares":78707270,"shares":78707270,"eps":0,"marketStatus":"已收盘","change":2.8,"latestTime":"11-17 16:08:13","open":132.2,"high":135.5,"low":130,"amount":4423690,"amplitude":0.041667,"askPrice":135.4,"askSize":50,"bidPrice":134.8,"bidSize":100,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":5,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":132,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.328564,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"12.62%","roe":"28.75%","lyrEps":0,"volumeRatio":0.328564,"shares":78707270,"dividePrice":0,"high":135.5,"amplitude":0.041667,"preClose":132,"low":130,"week52Low":97.5,"pbRate":"17.93","psRate":"20.79","week52High":147,"institutionHeld":0,"latestPrice":134.8,"committee":0.333333,"eps":0,"divideRate":0,"volume":33300,"delay":0,"ttmEps":0,"open":132.2,"prevYearClose":86.4,"prevWeekClose":132,"prevMonthClose":119.8,"prevQuarterClose":86.4,"fiveDayClose":129.4,"twentyDayClose":86.4,"sixtyDayClose":86.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2025-11-14","current":69.713569,"percent":0.842105,"low":41.43616,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"high":76.371175,"avg":61.983096,"sd":7.689241,"marketCap":10389359640},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640}],"updateTime":1763367875852},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1155189587","title":"海西新药涨超10%再创新高，较招股价涨近七成！四款核心仿制药贡献九成收入","url":"https://stock-news.laohu8.com/highlight/detail?id=1155189587","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155189587?lang=zh_cn&edition=fundamental","pubTime":"2025-11-12 14:43","pubTimestamp":1762929801,"startTime":"0","endTime":"0","summary":"11月12日，$海西新药$涨超10%再创新高，较招股价涨近七成！公开资料显示，海西新药是一家处于商业化阶段的制药公司。截至招股书披露日，海西新药获批上市的仿制药产品有15款，产品组合涵盖了多个治疗领域，包括消化系统、心血管系统、内分泌系统、神经系统等。从2024年的营收情况看，这四款核心仿制药贡献了海西新药超过九成的收入，达到4.25亿元。值得注意的是，海西新药已布局创新药研发管线。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2e9a463070c3ede9e070dabbce786938","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"gpt_icon":0},{"id":"2582344262","title":"港股异动 | 海西新药(02637)涨超10%再创新高 较招股价涨近七成 四款核心仿制药贡献九成收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2582344262","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582344262?lang=zh_cn&edition=fundamental","pubTime":"2025-11-12 14:36","pubTimestamp":1762929418,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药午后涨超10%，高见145.9港元，再创上市新高，较招股价86.4港元累涨近70%。公开资料显示，海西新药是一家处于商业化阶段的制药公司。截至招股书披露日，海西新药获批上市的仿制药产品有15款，产品组合涵盖了多个治疗领域，包括消化系统、心血管系统、内分泌系统、神经系统等。从2024年的营收情况看，这四款核心仿制药贡献了海西新药超过九成的收入，达到4.25亿元。值得注意的是，海西新药已布局创新药研发管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2e9a463070c3ede9e070dabbce786938","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02637"],"gpt_icon":0},{"id":"2582801415","title":"海西新药11月10日获主力加仓193.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582801415","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582801415?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 16:15","pubTimestamp":1762762523,"startTime":"0","endTime":"0","summary":"11月10日, 海西新药股价涨5.37%，报收129.40元，成交金额1627.1万元，换手率0.16%，振幅7.74%，量比1.10。海西新药今日主力资金净流入193.3万元，连续4日净流入，上一交易日主力净流入169.9万元。该股近5个交易日上涨7.28%，主力资金累计净流入841.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1095.3万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110161643975fcd7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110161643975fcd7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637","BK1191"],"gpt_icon":1},{"id":"2580163264","title":"【IPO月报】10月IPO赚钱效应继续：金叶超购逾万倍 长风药业首日可赚万七","url":"https://stock-news.laohu8.com/highlight/detail?id=2580163264","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580163264?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 16:09","pubTimestamp":1762157343,"startTime":"0","endTime":"0","summary":"10月新股IPO数量继续保持高位，认购情绪高涨，金叶国际集团认购倍数超万倍，同时，多只新股上市首日表现亮眼，市场交投活跃度显著提升，为香港资本市场注入新活力。业绩表现方面，10月30日，公司发布前三季度业绩，归属于上市公司股东的净利润约71.36亿元，同比增长46.58%;基本每股收益0.8455元。不过需要注意的是，长风药业在上市后未能延续首日的强劲走势，股价出现接连数日的回吐行情。目前，已获上市委员会批准，待上市数量为19家。","market":"other","thumbnail":"https://static.szfiu.com/news/20220324/YzUxYTE2NDgwOTA4NjcwODA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YzUxYTE2NDgwOTA4NjcwODA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968923","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00638","08549","BK1148","BK1191","BK1214","02637","BK1149","06031","06687","BK1171","BK1240","02575","02650","BK1109","02670","02652"],"gpt_icon":1},{"id":"2579187071","title":"海西新药10月30日主力净流入255.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2579187071","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579187071?lang=zh_cn&edition=fundamental","pubTime":"2025-10-30 16:15","pubTimestamp":1761812146,"startTime":"0","endTime":"0","summary":"10月30日, 海西新药股价涨6.80%，报收121.00元，成交金额2544.9万元，换手率0.27%，振幅9.44%，量比1.32。海西新药今日主力资金净流入255.0万元，上一交易日主力净流出2.6万元。该股近5个交易日上涨18.40%，主力资金累计净流入476.6万元；近20日主力资金累计净流入264.0万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030162022a6d6550d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030162022a6d6550d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637"],"gpt_icon":0},{"id":"2578100466","title":"10月19-25日港股IPO观察：5企业过聆讯，新能源与生物医药板块活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2578100466","media":"上市公司网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578100466?lang=zh_cn&edition=fundamental","pubTime":"2025-10-27 18:00","pubTimestamp":1761559200,"startTime":"0","endTime":"0","summary":"中国上市公司网据统计，10月19日至10月25日期间，港股市场共有7家公司提交招股书，5家公司通过聆讯。截至2025年6月30日，公司在全国建有5大生产基地、拥有26个授权IP及超过600个活跃SKU，包括糖果、饼干、膨化、巧克力、海苔零食五大产品类别。截至2025年6月30日，公司亦是中国拥有最多IP授权的IP趣玩食品企业。4)、10月22日，滨化股份首次向港交所递交招股书，拟在香港主板上市，联席保荐人为华泰国际、建银国际。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251027185716a6d0a590&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251027185716a6d0a590&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1149","06031","BK1214","06687","06166","02637","01384","00638"],"gpt_icon":1},{"id":"2578368609","title":"又一芯片龙头IPO过会丨IPO一周要闻","url":"https://stock-news.laohu8.com/highlight/detail?id=2578368609","media":"投资者网-思维财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578368609?lang=zh_cn&edition=fundamental","pubTime":"2025-10-26 08:03","pubTimestamp":1761436995,"startTime":"0","endTime":"0","summary":"近期，IPO市场亮点纷呈，港股市场与明星企业上市成为核心看点。本周周五过会的沐曦股份是一家GPU新秀，其科创板IPO于6月30日获受理，本次IPO拟募资39.04亿元。另外，从当前的IPO存量企业来看，截至目前，共有275家企业正在排队中，其中北交所存量IPO企业数量居首，达169家，占比超六成。此次IPO，广和通全球发售1.35亿股股份，首发募集资金约29.04亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251026080748a474df48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251026080748a474df48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637","00638","BK1214"],"gpt_icon":1},{"id":"2578538574","title":"港股IPO | 刷新港股新记录！“高端中国茶第一股”八马茶业招股获热捧","url":"https://stock-news.laohu8.com/highlight/detail?id=2578538574","media":"尚普IPO咨询","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578538574?lang=zh_cn&edition=fundamental","pubTime":"2025-10-25 17:01","pubTimestamp":1761382896,"startTime":"0","endTime":"0","summary":"港股热点事件八马茶业港股IPO定价50港元 超额认购2684倍创年内纪录10月24日，中国茶叶供应商八马茶业宣布以招股上限50港元定价，预计10月28日在港交所挂牌。此次公开发售部分吸引16.9万份申请，超额认购达2684倍，刷新港股年内新股超购倍数纪录。据了解，八马茶业此次发行900万股，其中10%为公开发售，募集资金总额约4.5亿港元。此次IPO未设回补机制，券商累计借出853亿港元孖展额，相当于公开发售额度的1896倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251025170922a4742093&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251025170922a4742093&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06980","02637","00638","06687","BK1214"],"gpt_icon":1},{"id":"2577593583","title":"海西新药10月24日主力净流出6.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2577593583","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577593583?lang=zh_cn&edition=fundamental","pubTime":"2025-10-24 16:15","pubTimestamp":1761293721,"startTime":"0","endTime":"0","summary":"10月24日, 海西新药股价跌0.45%，报收109.50元，成交金额1026.1万元，换手率0.12%，振幅6.27%，量比0.00。海西新药今日主力资金净流出6.9万元，上一交易日主力净流入273.4万元。该股近5个交易日上涨26.74%，主力资金累计净流入53.9万元；近20日主力资金累计净流入53.9万元，其中净流入天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024161632a4723cf1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024161632a4723cf1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637"],"gpt_icon":0},{"id":"2577332211","title":"港股异动 | 海西新药(02637)一度涨超12% 较招股价涨超三成 仿制药、创新药双线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2577332211","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577332211?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 14:09","pubTimestamp":1761199757,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药(02637)一度涨超12% ，高见114.9港元，较招股价86.4港元涨超30%。截至发稿，涨9.2%，报111.6港元，成交额2093.12万港元。据悉，海西新药是一家处于商业化阶段的制药公司，集研发、生产及销售能力于一体，具备在研创新药的管线。截至招股书披露日，海西新药获批上市的仿制药产品有15款，产品组合涵盖了多个治疗领域，包括消化系统、心血管系统、内分泌系统、神经系统等。公司亦已建立四款在研创新药的产品管线，涵盖癌症、眼科及呼吸系统疾病。海西新药此前在招股书中称，未来计划积极探索与跨国公司(MNC)合作的机会，以扩大公司的国际临床研究及商业化能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02637","06978","159992"],"gpt_icon":0},{"id":"2577844491","title":"又一药企登陆港股！医药行业赴港IPO热潮持续升温","url":"https://stock-news.laohu8.com/highlight/detail?id=2577844491","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577844491?lang=zh_cn&edition=fundamental","pubTime":"2025-10-21 15:43","pubTimestamp":1761032617,"startTime":"0","endTime":"0","summary":"如10月20日，海西新药正式登陆港股市场，本次募资总额达到约9.94亿港元。根据梳理，除了海西新药外，今年9月以来，至少还有9家A股药企宣布赴港IPO进展。如2025年9月30日一天，四家A股药企密集披露赴港IPO进展。业内表示，随着更多药企进入上市通道，港股正逐步巩固 “全球生物医药创新资本引擎” 的地位，而这场 IPO 热潮，或许只是中国医药产业国际化升级的序幕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021155037a46bda6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021155037a46bda6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637"],"gpt_icon":0},{"id":"1174412031","title":"异动解读 | 海西新药盘中大跌5.04%，高度依赖集采产品引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1174412031","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174412031?lang=zh_cn&edition=fundamental","pubTime":"2025-10-21 09:52","pubTimestamp":1761011555,"startTime":"0","endTime":"0","summary":"10月21日（周二）上午，港股上市新秀海西新药盘中大跌5.04%，引发市场广泛关注。该公司刚于10月20日在港交所挂牌上市，首日表现亮眼，收盘上涨20.60%。投资者需密切关注海西新药未来的业务转型进展和创新药管线的研发进度，以评估公司的长期发展前景。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4f283e08a8c52a60fffa4beefbde09d3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"gpt_icon":1},{"id":"1187748903","title":"异动解读 | 海西新药盘中大跌5%，高度依赖集采产品引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1187748903","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187748903?lang=zh_cn&edition=fundamental","pubTime":"2025-10-21 09:50","pubTimestamp":1761011444,"startTime":"0","endTime":"0","summary":"港股上市新秀海西新药今日盘中大跌5.04%，引发市场关注。该公司于10月20日刚刚在港交所挂牌上市，首日表现亮眼，收盘上涨20.60%。海西新药是一家商业化阶段的制药公司，主要依赖仿制药销售。尽管海西新药正在布局创新药研发管线，但多数项目仍处于早期临床阶段，短期内难以为公司贡献显著收入。市场分析师指出，海西新药需要加快创新药研发进程，提升研发效率，以在激烈的行业竞争中抢占先机。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4f283e08a8c52a60fffa4beefbde09d3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"gpt_icon":1},{"id":"1175052573","title":"港股综述｜三大指数齐涨！航空股延续近期涨势，机器人概念股集体“起飞”","url":"https://stock-news.laohu8.com/highlight/detail?id=1175052573","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175052573?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 16:34","pubTimestamp":1760949292,"startTime":"0","endTime":"0","summary":"A股行情A股收评：强势反弹！创业板指涨近2%，培育钻石、煤炭板块大涨10月20日，A股三大指数今日集体反弹，但午后涨幅有所收窄；截至收盘，沪指涨0.63%报3863点，深证成指涨0.98%，创业板指涨1.98%。全市场成交额1.75万亿元，较前一交易日缩量2031亿元，超4000股上涨。","market":"us","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSI","HSTECH","02637","09988","02670","00670"],"gpt_icon":1},{"id":"2576881237","title":"福建夫妇掌舵，海西新药IPO敲钟了","url":"https://stock-news.laohu8.com/highlight/detail?id=2576881237","media":"投资界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576881237?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 11:29","pubTimestamp":1760930940,"startTime":"0","endTime":"0","summary":"直至2012年，康心汕回到福建老家，和妻子冯岩、福建国资共同正式创立海西新药。截至2025年10月，海西新药共有15款仿制药获得国家药监局批准，已商业化产品多用于消化系统、心血管系统、内分泌系统、神经系统及炎症等疾病领域。不过好事多磨，海西新药原定于10月17日在港股正式挂牌交易，因未能刊发配发结果而延迟上市。其中，海西新药几乎所有的销售收入均来自销售仿制药。生物医药福建崛起一张版图海西新药落地福州，并非偶然。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020114151a6c2df22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020114151a6c2df22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","02637","BK1161"],"gpt_icon":1},{"id":"1153951196","title":"异动解读 | 海西新药上市首日盘中大涨21.53%，超额认购成热点","url":"https://stock-news.laohu8.com/highlight/detail?id=1153951196","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153951196?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 09:33","pubTimestamp":1760924003,"startTime":"0","endTime":"0","summary":"海西新药今日在港交所正式挂牌上市，盘中大涨21.53%，引发市场热烈关注。据悉，海西新药此次全球发售1150万股H股，最终发售价定为每股86.40港元，位于招股价区间的上限。公司香港公开发售部分获得3165.1倍超额认购，认购热情异常高涨。海西新药是一家专注于仿制药研发和生产的制药公司，产品涵盖消化系统、心血管系统等多个治疗领域。投资者对公司的增长潜力和市场地位表现出强烈信心，推动股价在首日交易中大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"01fb23fb7463438e1609e2def22b10ca","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"gpt_icon":0},{"id":"1147192935","title":"异动解读 | 海西新药上市首日大涨21.53%，IPO超额认购3165倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1147192935","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147192935?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 09:33","pubTimestamp":1760923987,"startTime":"0","endTime":"0","summary":"今日盘中，新上市的制药公司海西新药股价大涨21.53%，引起市场广泛关注。这家备受期待的新股今天正式在港交所挂牌交易，其强劲表现与其火爆的IPO认购情况密切相关。据悉，海西新药此前公布的招股结果显示，公司以每股86.40港元的上限价格定价，募集资金净额约9.4亿港元。分析人士指出，海西新药的强劲表现可能源于其在仿制药市场的领先地位和良好的财务表现。这些因素共同推动了投资者的热情，促使股价在上市首日出现大幅上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"01fb23fb7463438e1609e2def22b10ca","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"gpt_icon":1},{"id":"1120540781","title":"新股定价 | 海西新药上限定价、今日挂牌，公开发售超购3164倍，一手中签率1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120540781","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120540781?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 09:03","pubTimestamp":1760922205,"startTime":"0","endTime":"0","summary":"原计划于上周五(17日)上市的 $海西新药(02637)$ (02637.HK)公布招股结果，香港公开发售接获3,165.1倍认购，一手(50股)中签率1%，认购30万股始获稳派一手。国际发售录得6.3倍认购。最终发售价86.4港元，上限定价，集资净额9.4亿元。股份预期今日(20日)挂牌。创新药企海西新药本次拟全球发售1,150万股H股，公开发售占10%。招股价介乎69.88-86.4港元。基石投资者Harvest Oriental SP认购198.17万股，占发售总数17.23%。禁售承诺最后日期2026年4月19日。","market":"hk","thumbnail":"https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"01fb23fb7463438e1609e2def22b10ca","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"新股定价 | 海西新药上限定价、今日挂牌，公开发售超购3164倍，一手中签率1%","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"gpt_icon":0},{"id":"2576076107","title":"海西新药恢复周一上市，暗盘涨超50%！靠4款核心仿制药年入超4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576076107","media":"红星资本局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576076107?lang=zh_cn&edition=fundamental","pubTime":"2025-10-19 20:26","pubTimestamp":1760876807,"startTime":"0","endTime":"0","summary":"红星资本局10月19日消息，10月17日晚，福建海西新药创制股份有限公司（下称“海西新药”）在港交所发布公告称，将于10月20日（星期一）正式上市，发售价格为86.40港元/股。海西新药原定于10月17日在港股正式挂牌交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510193538034414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02637"],"gpt_icon":1},{"id":"1136460264","title":"福建海西新药创制(2637)热度飙升 逾31.6万份认购将于10月20日登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=1136460264","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136460264?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 22:06","pubTimestamp":1760709979,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司宣布，全球发售最终发售价确定为每股H股86.40港元。公司本次共发行11,500,000股H股，预期募资总额约为993.60百万港元，扣除约53.47百万港元上市开支后，预计所得款项净额约940.13百万港元。公司股份将于2025年10月20日（星期一）在香港联交所正式挂牌交易，每手买卖单位50股H股。香港发售方面，海西新药本次“火爆认购”有效申请数目316,139份，受理申请21,566份，认购倍数高达3,165.1倍。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}